Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data
Bio Expo
Champignondagen
  • News
  • Press Releases
  • Research
  • Business
  • Regulatory
  • Events and Conferences
The Pharma Data
  • Press Releases

BridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies

  • The Pharma Data
  • March 1, 2025

BridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies BridgeBio Oncology Therapeutics (BBOT), a clinical-stage biopharmaceutical company focused on developing next-generation small molecule therapies targeting RAS…

Read MoreBridgeBio Oncology and Helix Acquisition Announce Merger to Advance RAS & PI3Kα Therapies
  • Research

Astria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema

  • The Pharma Data
  • March 1, 2025

Astria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema Astria Therapeutics, Inc. (Nasdaq: ATXS), a leading biopharmaceutical company dedicated to developing innovative therapies for allergic and immunological diseases,…

Read MoreAstria Begins Phase 3 ALPHA-ORBIT Trial of Navenibart for Hereditary Angioedema
Vertex Gains CHMP Nod for KAFTRIO® Label Expansion
  • News

Vertex Gains CHMP Nod for KAFTRIO® Label Expansion in Rare CF Mutations

  • The Pharma Data
  • March 1, 2025

Vertex Gains CHMP Nod for KAFTRIO® Label Expansion in Rare CF Mutations Vertex Pharmaceuticals (Nasdaq: VRTX) has announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human…

Read MoreVertex Gains CHMP Nod for KAFTRIO® Label Expansion in Rare CF Mutations
Predictmedix AI Unveils Advanced AI Health Stations for US Market Expansion
  • Press Releases

Predictmedix AI Unveils Advanced AI Health Stations for US Market Expansion

  • The Pharma Data
  • March 1, 2025

Predictmedix AI Unveils Advanced AI Health Stations for US Market Expansion Predictmedix AI Expands into US Market with Launch of Advanced AI Health Stations Predictmedix AI Inc. (CSE: PMED) (OTC:…

Read MorePredictmedix AI Unveils Advanced AI Health Stations for US Market Expansion
SINOVAC Appoints New Board Following Privy Council Ruling
  • Press Releases

SINOVAC Appoints New Board Following Privy Council Ruling

  • The Pharma Data
  • March 1, 2025

SINOVAC Announces New Board Following Privy Council Judgment and Outlines Next Steps Sinovac Biotech Ltd. (NASDAQ:SVA) (“SINOVAC” or the “Company”), a leading biopharmaceutical company in China, has announced significant developments…

Read MoreSINOVAC Appoints New Board Following Privy Council Ruling
Identiv and Novanta Form Strategic Partnership to Accelerate RFID Adoption in Healthcare OEMs
  • Business

Identiv and Novanta Form Strategic Partnership to Accelerate RFID Adoption in Healthcare OEMs

  • The Pharma Data
  • February 28, 2025

Identiv and Novanta Forge Strategic Partnership to Accelerate Adoption of RFID Solutions in Healthcare OEMs Novanta Inc., a leading global technology supplier serving the medical device and life sciences markets,…

Read MoreIdentiv and Novanta Form Strategic Partnership to Accelerate RFID Adoption in Healthcare OEMs
Immune-Onc Doses First Patient in IO-108 Phase 1b2 Liver Cancer Trial with Roche
  • Research

Immune-Onc Doses First Patient in IO-108 Phase 1b/2 Liver Cancer Trial with Roche

  • The Pharma Data
  • February 28, 2025

Immune-Onc Therapeutics Doses First Patient with IO-108 in Global Phase 1b/2 Liver Cancer Study in Collaboration with Roche Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage biopharmaceutical company focused on developing…

Read MoreImmune-Onc Doses First Patient in IO-108 Phase 1b/2 Liver Cancer Trial with Roche
IPA and RIBOPRO Partner to Advance mRNA-Based Antibody Discovery and Expand Immunotherapy Frontiers
  • Business

IPA and RIBOPRO Partner to Advance mRNA-Based Antibody Discovery and Expand Immunotherapy Frontiers

  • The Pharma Data
  • February 28, 2025

IPA and RIBOPRO Forge Strategic Partnership to Revolutionize mRNA-Based Antibody Discovery and Expand Immunotherapy Horizons ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“IPA” or the “Company”), a global leader in AI-powered antibody…

Read MoreIPA and RIBOPRO Partner to Advance mRNA-Based Antibody Discovery and Expand Immunotherapy Frontiers
  • Business

Aurinia Pharmaceuticals Announces Q4 & 2024 Financial Results, Updates on Corporate Progress

  • The Pharma Data
  • February 28, 2025

Aurinia Pharmaceuticals Announces Strong Financial Performance for Q4 and Full Year 2024, Provides Corporate Updates Fourth Quarter and Full-Year 2024 Financial Performance Highlights Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH), a leading…

Read MoreAurinia Pharmaceuticals Announces Q4 & 2024 Financial Results, Updates on Corporate Progress
  • Press Releases

Genethon Showcases Innovations in Gene Therapy on Rare Disease Day

  • The Pharma Data
  • February 28, 2025

Genethon Advances Gene Therapy Innovations on Rare Disease Day 2025 Genethon, a pioneering gene therapy research organization founded by the AFM-Telethon, marks Rare Disease Day by showcasing groundbreaking technological advancements…

Read MoreGenethon Showcases Innovations in Gene Therapy on Rare Disease Day
  • News

Avitia Unveils AI-Powered Platform for Fast, Point-of-Care Cancer Testing

  • The Pharma Data
  • February 28, 2025

Avitia Unveils AI-Powered Platform for Fast, Point-of-Care Cancer Testing Avitia, an AI company providing end-to-end testing solutions to rapidly identify cancer mutations and applicable treatments, has officially launched its business…

Read MoreAvitia Unveils AI-Powered Platform for Fast, Point-of-Care Cancer Testing
  • Business

LEO Pharma’s Anzupgo® Meets Phase 3 Endpoint in China for Chronic Hand Eczema

  • The Pharma Data
  • February 28, 2025

LEO Pharma’s Anzupgo® Meets Phase 3 Endpoint in China for Chronic Hand Eczema LEO Pharma A/S, a global leader in medical dermatology, has announced positive results from the double-blind treatment…

Read MoreLEO Pharma’s Anzupgo® Meets Phase 3 Endpoint in China for Chronic Hand Eczema
PrevNext
UK Biotech Day
Global Clinical
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • Celltrion Unveils KRW 1.2 Trillion Expansion of Songdo Drug Substance Facilities, Boosting Total Capacity to 570,000 Liters
  • Eylea 8 mg Secures Approval in Japan for a Third Retinal Disease Indication
  • Bristol Myers Squibb Highlights Camzyos Data in oHCM at ACC 2026
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.